Ligand Pharmaceuticals Reports Third Quarter Financial Results

The Jupiter-based company posted a quarterly loss of $28.5 million despite beating analyst revenue estimates.

Updated on Oct. 29, 2026 in Corporate Finance

Isometric editorial illustration of a clean, geometric architectural laboratory model, representing the precision of corporate financial reporting. — Ligand Pharmaceuticals reported a third-quarter net loss of $28.5 million, even as quarterly revenue of $78.7 million surpassed analyst expectations. AI Illustration. Upload story photo >

Live Poll

Do you trust that quarterly earnings reports accurately reflect a company's long-term financial health?

Ligand Pharmaceuticals recorded a third-quarter net loss of $28.5 million, translating to a loss of $1.43 per share. Despite the bottom-line loss, the company exceeded market expectations with $78.7 million in revenue.

Why it matters

The company's adjusted earnings of $2.67 per share outperformed the $2.31 per share analysts had anticipated. These results reflect the firm's financial standing as it balances operational costs and stock option expenses.

Ligand Pharmaceuticals reported revenue of $78.7 million for the period, exceeding analyst estimates of $77.1 million. The firm posted an adjusted earnings figure of $2.67 per share, outperforming the projected $2.31 per share.

The players

Ligand Pharmaceuticals

A biopharmaceutical company based in Jupiter, Florida, that focuses on developing and acquiring technologies to help pharmaceutical partners discover and develop medicines.

The details

The reported loss of $28.5 million incorporates various stock option expenses and non-recurring costs. Looking ahead, the company maintains its financial guidance, projecting full-year revenue between $270 million and $310 million.

The financial reporting period covered the third quarter of 2026.
The company released these financial results on October 29, 2026.

Market Dynamics

The company provides an adjusted earnings figure that accounts for non-recurring costs, aligning with the standard practice established by the SEC's Regulation G disclosure requirements. This reporting approach helps investors parse core operational performance from one-time financial volatility.

The firm's ability to exceed revenue expectations may influence investor confidence and stock valuation moving forward. Retail investors should monitor future earnings releases to see if full-year targets remain within the provided guidance range.

The takeaway

Ligand Pharmaceuticals remains focused on its long-term financial targets despite reporting a quarterly net loss. Investors often look beyond net losses to adjusted figures to gauge the underlying health of a company's business model.